NEWS
IMAC Holdings Inc. Launches Subsidiary Ignite Proteomics and Announces Groundbreaking Precision Oncology Case Study Utilizing RPPA Technology
IMAC Holdings Inc. (Nasdaq: BACK) has launched a new subsidiary, Ignite Proteomics , introducing a groundbreaking precision oncology assay for breast cancer treatment using Reverse Phase Protein Array (RPPA) technology. This follows IMAC's acquisition of key assets from Theralink Technologies, Inc. A landmark clinical case study published in npj Precision Oncology demonstrates the power of RPPA in precision oncology.
The case study highlights a 57-year-old woman with metastatic triple-negative breast cancer who achieved a complete response to therapy guided by Ignite's RPPA-based analysis. The assay identified HER2 expression and activation, missed by conventional methods, leading to successful treatment with trastuzumab deruxtecan (T-DXd).
Ignite Proteomics offers the only commercially available and clinically validated assay measuring both expression and activated protein drug target levels in breast tumors, potentially revolutionizing targeted cancer therapies.
The case study highlights a 57-year-old woman with metastatic triple-negative breast cancer who achieved a complete response to therapy guided by Ignite's RPPA-based analysis. The assay identified HER2 expression and activation, missed by conventional methods, leading to successful treatment with trastuzumab deruxtecan (T-DXd).
Ignite Proteomics offers the only commercially available and clinically validated assay measuring both expression and activated protein drug target levels in breast tumors, potentially revolutionizing targeted cancer therapies.
免責聲明：社區由Moomoo Technologies Inc.提供，僅用於教育目的。
更多信息
評論
登錄發表評論
